In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Curocell Inc., Daejeon, Republic of Korea.

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Michael Tees, MD, discusses the preliminary safety outcomes observed for an allogeneic chimeric antigen receptor T-cell therapy for large B-cell lymphoma. In the largest study of CAR T-cell therapy, ...

In an interview with Targeted Oncology, Frederick Locke, MD, discussed the mechanism of action of 2 allogeneic CD19-directed CAR T-cell products and next steps for their evaluation for the treatment ...

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now ...

Current issues include the high costs and complexities associated with manufacturing CAR T-cells, especially in both autologous and allogeneic settings. The process involves intricate viral ...